



Disease Eradication

Why invest in Disease Eradication?

This portfolio seeks returns by investing in companies that currently have (or are in clinical trials for) products that treat the world's most prevalent diseases.

Key Trends



Diseases have seen significant growth

Harvard Kennedy School notes that the number of outbreaks, and the types of diseases, have both increased significantly since 1980. Outbreaks of newer diseases like Zika, as well as older ones like yellow fever, continue to rise.



Noncommunicable diseases kill millions

Noncommunicable diseases (NCDs) kill 40 million people each year, equivalent to 70% of all deaths globally. Cardiovascular diseases account for most NCD deaths annually, followed by cancers, respiratory diseases, and diabetes.



New drug therapies will reduce global impact

We target our investments in pharmaceutical, biotech, and other companies developing novel approaches to combating today's biggest health challenges.

Characteristics


Advisory Fee	0.75%
Holdings	57
Market Cap	\$47.84B
Dividend Yield	0.87
Debt/Capital	37.21
P/E (FY1 Est.)	51.57
Beta	1.17
EV/FCF	18.63
EV/Sales	5.65
P/S	5.74
EPS Growth (3-5 year Estimated)	21.46

Performance




Portfolio Distribution

Distribution by Market Cap




● Small - 7.90%
 ● Mid - 45.99%
 ● Large - 45.82%
 ● Cash - 0.29%

Distribution by SIC Sub-Sector %



Portfolio Risk Level: Moderately Aggressive



Given the market capitalization and availability of companies in the Disease Eradication theme, this portfolio will likely be fairly concentrated, which means it's also likely to see short-term volatility (prices going up and down). Therefore, this portfolio should be seen as a long-term investment.

Top Ten Holdings

(42.18% of portfolio)

Company	Ticker	Weight	Description	MSCI ESG Rating
Celgene Corp.	CELG	4.39%	Celgene is the driving force behind a number of new cancer-treating therapies and have a patient-first approach.	BBB
Biogen, Inc.	BIIB	4.29%	Biogen has made breakthrough discoveries for treatment of chronic lymphocytic leukemia as well as non-Hodgkin's lymphoma.	A
Resmed, Inc.	RMD	4.25%	ResMed is a global manufacturer of CPAP masks, machines and other products that diagnose, treat or help manage sleep-disordered breathing, and other respiratory conditions.	AA
Gilead Sciences, Inc.	GILD	4.24%	One of the largest biopharmaceutical companies in the world. Their social impact efforts extend from those with life-threatening diseases to public health and local communities.	AA
Becton, Dickinson and Co.	BDX	4.24%	Becton, Dickinson and Co. is pioneering advanced medical research and genomics in the treatment of infectious diseases and cancer.	BBB
Vertex Pharmaceuticals, Inc.	VRTX	4.21%	Vertex's clinical development programs are focused on cystic fibrosis. They also have more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.	AA
Eli Lilly & Co.	LLY	4.19%	The company has an expansive portfolio of treatments in the areas of oncology, cardiovascular, diabetes, critical care, neuroscience, men's health and musculoskeletal fields.	A
Merck & Co., Inc.	MRK	4.16%	Merck produces seven different pharmaceuticals used in oncology today, with the goal of helping people fight cancer.	A
Amgen, Inc.	AMGN	4.12%	Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses.	A
Incyte Corp.	INCY	4.09%	Incyte is a biopharmaceutical research company focused on the development of immune-based therapies in oncology.	B

Portfolio Management Team

Dave Fanger, CFA

20 years of financial services experience

BS, Actuarial Science, Ball State University

MBA, UCLA Anderson

Fellow of the Society of Actuaries

Amberjae Freeman

12 years of Impact and ESG research experience

BA, Global & International Studies, UC Santa Barbara

Master of Arts, Global Political Economy, UC Santa Barbara

Jake Raden

9 years of financial services experience

BA, Environmental Studies, University of Chicago

MPH, Public Health Ethics and Policy, Creighton University

Lily Bowles, FSA

8 years of shareholder engagement experience.

BA, Political & Social Thought, University of Virginia

MSc, International Development, London School of Economics

Glossary

Advisory fee – The percentage of your account value that an investment company or manager charges to handle your account. Also, sometimes called a management fee. Swell clients pay a single fee of 0.75% per year on their invested assets for brokerage, custodial, investment advisory, and other related services defined in our [Advisory Agreement](#).

Benchmark – A standard against which the performance of a security or investment manager can be measured. Generally, broad market and market-segment stock indexes are used for this purpose.

Beta – A measure of how risky a company's stock is relative to the broader market. The market has a beta of 1.0, and individual stocks are ranked by how much they deviate from the market's beta. If a stock swings more than the market over time, it means that its beta is higher than 1.0. If it moves less than the market, the stock's beta is less than 1.0. High-beta stocks are supposed to be riskier, but also provide potential for higher returns; similarly, low-beta stocks pose less risk, but also lower returns.

Debt to capital – The ratio of total debt divided by total debt plus total shareholders' equity.

Dividend yield – The annual dividends per share paid by a company divided by its security price.

Earnings per share – The amount of income earned during a period per share of common stock.

Earnings per share projected growth rate (EPS growth) – The compounded annualized (three or five year) projected rate of growth of a company's earnings.

Enterprise value (EV) – Total company value (the market value of debt, common equity, and preferred equity) minus the value of cash and investments.

Enterprise value to free cash flow (EV/FCF) – A financial ratio that compares the total value (as measured by enterprise value) of the company to its free cash flow.

Enterprise value to sales (EV/S) – A financial ratio that compares the total value (as measured by enterprise value) of the company to its sales.

Equity (i.e., stock) – An instrument that signifies an ownership position, or equity, in a corporation, and represents a claim on its proportionate share in the corporation's assets and profits.

Free cash flow (FCF) – The actual cash that would be available to the company's investors after making all investments necessary to maintain the company as an ongoing enterprise (also referred to as free cash flow to the firm); the internally generated funds that can be distributed to the company's investors (e.g., shareholders and bondholders) without impairing the value of the company.

Market capitalization – The size of a company. To calculate a company's market cap, multiply the total number of a company's outstanding shares by the current price per share. Swell uses the same market cap thresholds as the [Russell Indexes](#): Large cap (approximately \$26.3 billion to \$926.9 billion), mid cap (approximately \$2.9 billion to \$26.3 billion), and small cap (approximately \$159.2 million to \$2.9 billion).

MSCI ESG Ratings – MSCI ESG Research products and services are provided by MSCI ESG Research LLC, and are designed to provide in-depth research, ratings, and analysis of environmental, social, and governance-related business practices to companies worldwide. MSCI ESG Research LLC is a registered investment adviser under the Investment Advisers Act of 1940 and a subsidiary of MSCI Inc.

Price to earnings (P/E) one-year forward estimate (FY1 Est.) – Price of the stock divided by its one-year projected forward earnings.

Price-to-sales ratio (P/S) – Calculated by dividing the stock's current price per share by its sales.

Risk level – Swell's portfolio risk levels are based on their asset class. Swell portfolios are typically moderate to high risk based on the following scale:

Risk level	Asset Class
5	International Equities
4	US Small & Mid Cap Equities
3	US Large Cap Equities
2	Fixed Income Securities
1	Cash & Cash Equivalents

Sustainable Industry Classification System® (SICS®) uses an impact-focused methodology categorizing companies under a sustainability lens. SICS builds on and complements traditional classification systems by grouping companies into sectors and industries in accordance with a fundamental view of their business model, their resource intensity and sustainability impacts, and their sustainability innovation potential. For unclassified companies we supplement with GICS.

Volatility – One gauge of how risky it is to own a security or portfolio. It provides a measure of how much the price tends

Disclosures

Sources:

1. "Global trends in human infectious disease: Rising number of outbreaks, fewer per-capita cases," Journalist's Resource: "Global rise in human infectious disease outbreaks," Journal of the Royal Society Interface, 2014; World Health Organization noncommunicable diseases factsheet, April 2017.
2. The performance shown is the actual results of an investment account held by an affiliate assuming a 0.75% annual advisory fee. Performance shown is net of fees and transaction-related expenses and includes reinvestment of dividends greater than \$1 dollar. The S&P 500 Total Return Index benchmark data was provided by Xignite.
3. Portfolio metrics and weights are provided by Bloomberg.

*All portfolio holdings are available for review on our website at www.swellinvesting.com

Benchmarks

The Standard and Poor's 500 (S&P 500) Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad U.S. domestic economy through changes in the aggregate market value of 500 stocks representing all major industries. Any comparison to the S&P 500 Index, or to any other benchmark, is shown for illustrative purposes only. Swell's portfolios differ from the S&P 500 in that, among other factors, Swell's portfolios are managed, undiversified, bear fees, and may vary materially in volatility. Swell uses the total return index of the S&P 500 (SPXT).

About Risk

The description below is an overview of the risks entailed in our investment strategies and is not intended to be complete. All investing involves a risk of loss that clients should be prepared to bear, and the investment strategies offered by Swell could lose money over short or long periods. Performance could be hurt by a number of different market risks including but not limited to:

- **Stock Market Risk.** An investment in individual securities or in a portfolio of securities could lose money. We cannot give any guarantee that we will achieve the client's investment objectives or that any client will receive a return of their investment. Stock markets tend to move in cycles, with periods of rising prices and periods of falling prices.
- **Individual Equity Risks.** Under strategies utilizing equity securities, the portfolios are subject to the risk that stock prices may fall over short or extended periods of time. Individual companies may report poor results or be negatively affected by industry and/or economic trends and developments. The prices of securities issued by such companies may suffer a decline in response. These factors contribute to price volatility, which is the principal risk of investing in equity securities.
- **Risks Related to Company Size.** Swell's strategies will primarily invest in small-capitalization and mid-capitalization stocks, which are often more volatile and less liquid than investments in larger companies. The frequency and volume of trading in securities of smaller and mid-size companies may be substantially less than is typical of larger companies. Therefore, the securities of smaller and mid-size companies may be subject to greater and more abrupt price fluctuations. In addition, smaller and mid-size companies may lack the management experience, financial resources, and product diversification of larger companies, making them more susceptible to market pressures and business failure.
- **Risks Associated with the Underlying Business.** Investments in securities entails all the risks associated with the underlying businesses, including reliance on a company's managers and their ability to execute business strategies. In addition, all businesses face risks such as adverse changes in regulatory requirements, interest rate and currency fluctuations, general economic downturns, changes in political situations, market competitions, and other factors. Swell will not have day-to-day control over any company in which it invests for clients.
- **Diversification Risks.** Swell's investment portfolios will be concentrated in specific industry groups and will not be considered diversified portfolios. Such industry concentration could have a material effect on the performance of the portfolio if the particular industry sector in which the portfolio is invested does not perform well or falls out of favor. Non-diversified portfolios may experience greater volatility than diversified portfolios. The risks of investing in a non-diversified portfolio may also be greater than the risks of investing in a diversified portfolio.

There can be no assurance that a client's investment objectives will be achieved and no inference to the contrary is being made. Prior to entering into an agreement with Swell, a client should carefully consider that volatility from investing in the stock market can occur and that over time the client's assets may fluctuate and at any time be worth more or less than the amount invested.

Swell does not represent, guarantee, or imply that the services or methods of analysis employed by us can or will predict future results, successfully identify market tops or bottoms, or insulate clients from losses due to market corrections or declines.

Disclaimer: Swell Investing LLC is an SEC registered investment adviser. Brokerage services provided to clients of Swell Investing LLC by Folio Investments, Inc., an SEC registered broker-dealer and member FINRA/SIPC.

Investments: Not FDIC Insured • No Bank Guarantee • May Lose Value. Investing in securities involves risks, and there is always the potential of losing money when you invest in securities. Please consider your objectives and Swell's fees before investing. Past performance does not guarantee future results.

Swell portfolios are not mutual funds; they are separately managed account (SMA) portfolios.

This factsheet is not an offer, solicitation of an offer, or advice to buy or sell securities in jurisdictions where Swell is not registered. Registration does not imply a certain level of skill or training. Nothing in this article should be construed as tax advice, an offer, solicitation, or recommendation to purchase or sell any security. This factsheet is not intended as investment advice, and Swell does not represent in any manner that the circumstances described herein will result in any particular outcome. Investment advisory services are only provided to investors who become Swell clients. Any past performance provided is for illustrative purposes only and is not indicative of future investment results. As with any investment, there is the potential for profit and the risk of loss.

Have more questions?

visit support.swellinvesting.com